<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415750</url>
  </required_header>
  <id_info>
    <org_study_id>ENHVIE</org_study_id>
    <nct_id>NCT03415750</nct_id>
  </id_info>
  <brief_title>Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants</brief_title>
  <acronym>ENHVIE</acronym>
  <official_title>A Single-center,Randomized,Open-label,12 Months Study,2 Parallel Group to Compare the Efficacy of Everolimus Combination + Tacrolimus in Regression of Left Ventricular Hypertrophy vs Tacrolimus + MMF in Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edoardo Melilli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study with two parallel group to compare the efficacy of everolimus combination +&#xD;
      tacrolimus in regression of left ventricular hypertrophy vs tacrolimus + mycophenolate&#xD;
      mofetil in renal transplant patients in the maintenance phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, randomized, open-label, 12 months study, with two parallel group to compare&#xD;
      the efficacy of everolimus combination + tacrolimus in regression of left ventricular&#xD;
      hypertrophy vs tacrolimus + mycophenolate mofetil in renal transplant patients in the&#xD;
      maintenance phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Left Ventricular Hypertrophy</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of Left Ventricular Hypertrophy more or equal than 10 g/m2 in the study group compared to control group at 12 months. Regression of LVH is defined as a decrease of 10 g/m2 compared to baseline value. Cardio nuclear magnetic resonance will be performed to evaluate left ventricular hypertrophy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypertrophy, Left Ventricular</condition>
  <arm_group>
    <arm_group_label>Everolimus arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will remain in Tacrolimus + Mycophenolate mofetil combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Conversion from Mycophenolate mofetil to Everolimus</description>
    <arm_group_label>Everolimus arm</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Patients will remain in Tacrolimus + Mycophenolate mofetil</description>
    <arm_group_label>Mycophenolate arm</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Everolimus arm</arm_group_label>
    <arm_group_label>Mycophenolate arm</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient's signed informed consent prior to any study-related procedure.&#xD;
&#xD;
          -  Adult patients (&gt; 18 years), renal transplant recipients of more than 1 year of&#xD;
             evolution.&#xD;
&#xD;
          -  Patients receiving maintenance immunosuppression with tacrolimus delayed release&#xD;
             (Envarsus®) and MMF / MPA.&#xD;
&#xD;
          -  Patients with Left Ventricular Hypertrophy detected by Cardio-NMR.&#xD;
&#xD;
          -  Subjects with glomerular filtration rate &gt;30 ml/min (calculated by CKD-EPI) and stable&#xD;
             in the last two analytical determinations (variation &lt;20%).&#xD;
&#xD;
          -  No known contraindications to the use of Mtor inhibitors (previous intolerance, deep&#xD;
             vein thrombosis , pulmonary embolism, proteinuria &gt; 0.5 g/day)&#xD;
&#xD;
          -  Patients with Hb levels ≥ 11 gr/dl.&#xD;
&#xD;
          -  Patients with blood pressure &lt;140/90 mmHg in the hospital visits or &lt;135/85 mmHg at&#xD;
             home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's signed informed consent prior to any study-related procedure.&#xD;
&#xD;
          -  Adult patients (&gt; 18 years), renal transplant recipients of more than 1 year of&#xD;
             evolution.&#xD;
&#xD;
          -  Patients receiving maintenance immunosuppression with tacrolimus delayed release&#xD;
             (Envarsus®) and MMF / MPA.&#xD;
&#xD;
          -  Patients with Left Ventricular Hypertrophy detected by Cardio-NMR.&#xD;
&#xD;
          -  Subjects with glomerular filtration rate &gt;30 ml/min (calculated by CKD-EPI) and stable&#xD;
             in the last two analytical determinations (variation &lt;20%).&#xD;
&#xD;
          -  No known contraindications to the use of Mtor inhibitors (previous intolerance, deep&#xD;
             vein thrombosis , pulmonary embolism, proteinuria &gt; 0.5 g/day)&#xD;
&#xD;
          -  Patients with Hb levels ≥ 11 gr/dl.&#xD;
&#xD;
          -  Patients with blood pressure &lt;140/90 mmHg in the hospital visits or &lt;135/85 mmHg at&#xD;
             home.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edoardo Melilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Edoardo Melilli</investigator_full_name>
    <investigator_title>Principal Investigator MD</investigator_title>
  </responsible_party>
  <keyword>Renal transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

